SS Innovations International (NASDAQ: SSII) has supported 195 robotic telesurgeries using its SSi Mantra surgical robotic system as of September 28, 2026, the company reported, including cardiac procedures and operations conducted across significant geographic distances. The milestone highlights the growing viability of remote surgery, in which a surgeon operates on a patient located miles away using robotic arms and high-speed communications links.
The telesurgery figures come alongside broader commercial momentum. SS Innovations said its installed base rose 45% to 244 systems across 12 countries, with cumulative surgical procedures reaching 14,503 and approximately 1,500 physicians trained on the platform. Recent international expansion includes new robotic cardiac surgery programs in Colombia, Sri Lanka, and India. A detailed account of the company’s progress is available at https://ibn.fm/S3TFq.
The numbers matter because telerobotic surgery could extend specialist care to regions that lack cardiac surgeons or other highly trained operators. By enabling procedures over distance, the technology may reduce the need for patients to travel to major medical centers, potentially lowering costs and waiting times. SS Innovations has positioned its products around affordability and accessibility, a contrast to the high price points that have historically limited robotic surgery to well-funded hospitals.
Headquartered in India but structured as a U.S. company, SS Innovations develops the SSi Mantra system and the SSi Mudra suite of surgical instruments, which support a range of robotic procedures including cardiac surgery. The company is also pursuing U.S. Food and Drug Administration clearance and European Union CE marking to support entry into additional markets. Those regulatory steps are significant because U.S. and EU approvals would open some of the world’s largest health care markets to the platform and could accelerate adoption among hospitals that require such certifications before purchasing.
The company’s expansion comes as advances in surgical robotics and communications technology create new opportunities for remote medical procedures. For investors, the 45% growth in installed systems and the rising procedure volume offer measurable signs of traction. For health care providers, the key question is whether telerobotic surgery can maintain safety and reliability at scale, particularly for complex cardiac operations. SS Innovations’ disclosed figures suggest that adoption is moving beyond pilot programs, though the company will need to demonstrate consistent clinical outcomes to win broader acceptance.
More information about the company is available at SSInnovations.com, and the latest news and updates relating to SSII can be found in the company’s newsroom at https://ibn.fm/SSII. The announcement was distributed through TechMediaWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other communications services. Full terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.
